NeuroRX

, Volume 1, Issue 2, pp 206–212

Molecular neuroimaging in Alzheimer’s disease

Authors

    • School of Public Health and Helen Wills Neuroscience InstituteUniversity of California, Berkeley
Article

DOI: 10.1602/neurorx.1.2.206

Cite this article as:
Jagust, W. Neurotherapeutics (2004) 1: 206. doi:10.1602/neurorx.1.2.206

Summary

Considerable data exist to support the use of positron emission tomography (PET) and single photon emission computed tomography (SPECT) scanning as biomarkers for Alzheimer’s disease (AD). The techniques are reasonably sensitive and specific in differentiating AD from normal aging, and recent studies with pathological confirmation show good sensitivity and specificity in differentiating AD from other dementias. These techniques also can detect abnormalities in groups of asymptomatic and presymptomatic individuals and may be able to predict decline to dementia. However, there are a number of existing questions related to the use of these techniques in samples that are fully representative of the spectrum of patients with dementia. For example, it is unclear how well PET and SPECT perform in comparison to a clinical diagnosis obtained in the same patient group, when autopsy is used as a gold standard. It will also be important to know what PET and SPECT add to the certainty of diagnosis in addition to the standard clinical diagnosis. Despite these unanswered questions, PET and SPECT may have application as biomarkers for AD in a number of clinical and research settings, especially in academic centers, where most of the existing studies have been done.

Key Words

PETSPECTfunctional imagingmolecular imagingAlzheimer’sglucose metabolismblood flow
Download to read the full article text

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc 2004